• Successfully defended a branded pharmaceutical company in the Bystolic® “pay for delay” patent-settlement litigation challenging six so-called “side deals,” obtaining complete dismissal under Rule 12(b)(6) of all antitrust and consumer-protection claims filed by direct-purchaser, indirect-purchaser, and opt-out retailer plaintiffs. The Second Circuit affirmed on appeal.

• Successfully defended a global electronics manufacturer in a multibillion-dollar price-fixing case as part of the trial team that won a complete defense verdict after a multi-week jury trial.

• Successfully defended a nationwide franchisor, obtaining an early dismissal of all franchise product-tying and breach-of-contract claims where franchisees alleged that they were forced to purchase supplies at inflated prices.

• Successfully defended a healthcare company against “sham litigation” claims after a patent was invalidated. The district court dismissed all antitrust and consumer-protection claims as well as claims by a qui tam plaintiff under the False Claims Act. The client was the only defendant dismissed in all three cases.

• Successfully defended a fintech company as part of the appellate team securing a complete win in the Eleventh Circuit, which affirmed a Rule 12(b)(6) dismissal of common law tort and securities challenges relating to so-called “short squeeze” trading of meme stocks.

• Successfully eliminated nearly $200 million in alleged damages against a construction company in a high-stakes construction dispute after a month-long trial.

• Successfully defended a branded pharmaceutical company against “product hopping” monopolization claims in the Doryx® antitrust litigation, securing the first-ever grant of summary judgment against such claims. The Third Circuit affirmed on appeal.

• Successfully represented a construction manufacturer in multiple price-fixing investigations by the FTC and the DOJ’s Antitrust Division.

• Successfully defended a biotechnology company in royalty disputes under license agreements, implicating over a billion dollars in alleged underpayments.

• Successfully secured full indemnification for a healthcare licensor concerning a multimillion-dollar dispute filed against both the licensor and licensee.

• Successfully enforced a non-class arbitration provision in a wholesaler distribution agreement, eliminating billions of dollars in alleged class-wide damages.

• Successfully opposed direct-purchaser plaintiffs’ motion for class certification in the AndroGel® “reverse payment” litigation in which plaintiffs sought several billion dollars in alleged class damages from branded and generic pharmaceutical manufacturers. The court denied the motion for class certification in its entirety.

• Successfully defeated alleged “reverse payment” and “product hopping” claims against a branded pharmaceutical company in the Asacol® antitrust litigation. On the eve of opening arguments, the First Circuit stayed the trial and granted a rare interlocutory appeal, ultimately vacating the federal district court’s certification of an indirect-purchaser class.

• Successfully defended a global branded pharmaceutical company in the In re HIV Antitrust Litigation, including by (i) securing dismissal of all “product hopping” and joint-venture claims on summary judgment, (ii) obtaining dismissal of a direct-purchaser complaint on statute-of-limitations grounds, despite allegations of fraudulent concealment, and (iii) defeating a motion to certify a class consisting of direct purchasers of HIV treatment Complera®. A jury subsequently found for defendants on all remaining claims at trial.

• Successfully represented a power and infrastructure manufacturing company in a government investigation concerning alleged bid-rigging practices.

• Successfully defended two generic pharmaceutical manufacturers in the seminal FTC v. Actavis litigation concerning “reverse payment” claims. After the U.S. Supreme Court’s decision in FTC v. Actavis, Inc., 570 U.S. 136 (2013) and follow-on litigation by the FTC in federal district court, the FTC voluntarily dismissed its claims with prejudice for zero damages, no liability, and no injunctive relief beyond that agreed to previously by the client’s corporate parent in a prior unrelated matter.

• Successfully represented a professional sports organization in various merger and non-merger investigations by the DOJ’s Antitrust Division, the Canadian Competition Bureau, and several state attorneys general.

• Successfully represented an internet-advertising company concerning a consumer-protection investigation by the Federal Trade Commission’s Bureau of Consumer Protection.

• Successfully counseled a global retailer on warranty risks and compliance under federal and state laws.

• Successfully counseled a global automotive company on franchise-dealer laws and compliance.

• Successfully counseled an international trade association concerning the FTC’s proposed rule on non-compete agreements.

• Successfully represented an auto-parts manufacturer in obtaining merger clearance without any divestitures.

*Includes matters prior to joining Pierson Ferdinand